Amy Johnson, PhD, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196).
Amy Johnson, PhD
Articles by Amy Johnson, PhD
Latest Updated Articles
Dr. Amy Johnson on Research Into Acalabrutinib as a Treatment for CLLPublished: December 11th 2015 | Updated: